Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: A randomized study

Sexually Transmitted Diseases

Volumn 30, Issue 3, 2003, Pages 226-231

  Romanowski, Barbara ^a,c   Marina, Raymond B ^b   Roberts, Jeremy N ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VALACICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; VALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL HERPES; HEADACHE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT FAILURE; VIRUS REACTIVATION; VIRUS SHEDDING; AGED; CANADA; DRUG ADMINISTRATION; MIDDLE AGED; NOTE; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CANADA; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; VALINE;

EID: 0037335901     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200303000-00010     Document Type: Article

References (22)

1. Goldmeier D, Johnson A, Byrne M, Barton S. Psychosocial implications of recurrent genital herpes simplex virus infection. Genitourin Med 1988; 64:327-330.
2. Emmert DH. Treatment of common cutaneous herpes simplex virus infections. Am Fam Phys 2000; 61:1697-1704.
3. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75:398-402.
4. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. J Clin Invest 1997; 99:1092-1097.
5. Stanberry L, Cunningham A, Mertz G, et al. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res 1999; 42:1-14.
6. Perry CM, Faulds D. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754-772.
7. Ormrod D, Scott LJ, Perry CM. Valacyclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 2000; 59:39-63.
8. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single and multipledose administration to normal volunteers. Clin Pharmacol Ther 1993; 54:595-605.
9. Patel R, Bodsworth NJ, Woolley P, et al. Valacyclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med 1997; 73:105-109.
10. Reitano M, Tyring S, Lang W, et al. Valacyclovir for the suppression of recurrent genital herpes simplex virus infections: a large-scale dose finding study. J Infect Dis 1998; 178:603-610.
11. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K, Valciclovir HSV Study Group. A large-scale, placebo-controlled, doseranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-1735.
12. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valacyclovir versus acyclovir in patient initiated treatment of recurrent genital herpes: a randomized, double blind clinical trial. Genitourin Med 1997; 73: 110-116.
13. Taback N, Bradley C. Validation of the Genital Herpes Treatment Satisfaction Questionnaire (GHERPTSQ) in Status and Change versions [abstract 230]. Presented at the Annual Conference, International Society for Quality of Life Research. Vancouver, Canada, 2000.
14. Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Qual Life Res 1998; 7:143-153.
15. Gart JJ. An exact test for comparing matched proportions in crossover designs. Biometrika 1969; 56:75-80.
16. Mainland D. Elementary Medical Statistics. 2nd ed. Philadelphia: Saunders, 1963.
17. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. New York: Chapman and Hall, 1989.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
19. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc 1972; 34 Series B:187-220.
20. Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet Gynecol 1999; 94:103-106.
21. Jeffries D, Barton S, Johnson R, Emery V. Issues in herpes management. Antiviral Chem Chemother 1994; 5:23-29.
22. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:105-111.